Introduction {#S5}
============

Risk-stratification in newly diagnosed prostate cancer (PCa) aids physicians and patients to choose an optimal management approach. The most widely used risk-classification system (D'Amico) was developed in 1998 ([@R1]) and has been adapted by the National Comprehensive Cancer Network (NCCN). ([@R2]) Currently, the NCCN high-risk localized PCa classification (comprising up to 26% of newly diagnosed men ([@R3])), defined as biopsy Gleason sum ≥8 or PSA \>20 ng/ml or clinical stage ≥T3a, helps identify men with localized disease who are at high recurrence and progression risk after treatment.

However, cancer-specific outcomes within high-risk PCa vary dramatically. Ten-year metastasis free survival (MFS) can range from 70% to 95% depending on biopsy Gleason sum and clinical stage among high-risk men who undergo radical prostatectomy (RP). ([@R4]) Biochemical recurrence among high-risk men can vary by over 50% at 10 years. ([@R5]) Pre-operative factors that predict adverse outcomes in high-risk men have been subsequently identified, including multiple high-risk features, Gleason sum 9--10, PSA \>10 ng/ml, clinical stage ≥T2b, and higher volume of high-grade cancer. ([@R6],[@R7])

This heterogeneity of clinical outcomes suggests the existence of high-risk sub-populations. We hypothesize that commonly used clinical variables can be used to distinguish subsets of men with high-risk disease, while preserving the ease-of-use and point-of-care clinical applicability of existing NCCN risk strata. Identification of men within the high-risk cohort who either experience relatively good oncologic outcomes (high-risk) or the worst outcomes (very-high-risk, or VHR) despite aggressive treatment can aid pre-treatment risk stratification and also assist in the selection of potential candidates for multimodal therapy or clinical trials. ([@R8])

Here, by exploring alternate permutations of known pre-treatment prognostic variables, we identified a subset of men within the NCCN high-risk cohort who were at *very*-high risk (VHR) for adverse oncologic outcomes.

Materials and Methods {#S6}
=====================

The IRB-approved institutional RP database containing 21039 men was queried to identify men with NCCN high-risk localized PCa (Gleason sum 8--10, PSA \>20 ng/ml, or clinical stage ≥T3a) ([@R2]) who underwent RP. The following groups were excluded from analysis: men treated in the pre-PSA era (1571); those who received neoadjuvant hormonal treatments (876); men with no follow-up data (6499); and men with incomplete pre-treatment staging (307). Of 11786 evaluable patients, 7085 (60.1%) were NCCN very-low or low-risk, 3948 (33.5%) were intermediate-risk, and 753 (6.4%) were high-risk. In the high-risk cohort detailed biopsy information was evaluated, including number of positive/total cores, primary/secondary Gleason patterns in each core, and maximum percent cancer in each core for each Gleason pattern present. Multiple high-risk features was defined as having two or three of the individual NCCN high-risk criteria.

As a preliminary analysis, associations of previously described prognostic factors (number of NCCN high risk features, increasing biopsy Gleason sum, increasing PSA, PSA velocity, more advanced clinical stage, and increasing volume of high-grade cancer on biopsy) with metastasis and cancer-specific death were calculated in order to validate their further use in the present high-risk cohort. Pre-operative PSA velocity data was available for 234 men. Twenty-eight alternate permutations of adverse prognostic factors served as test definitions of VHR criteria. For each VHR test definition, Cox proportional hazards modeling was used to calculate unadjusted hazard ratios for metastasis, cancer-specific, and all-cause mortality. VHR test definitions that had hazard ratios in the top quartile for both metastasis and cancer-specific mortality were selected for further evaluation by multivariable analysis after adjusting for variables that were not already incorporated into the VHR test definitions: age, year of surgery, and perineural invasion. Only patients with NCCN high-risk cancer were included in all analyses.

The final criteria for VHR PCa were selected based on adjusted hazard ratios for metastasis and cancer-specific mortality and cohort size. The resulting VHR cohort was compared to the remainder of high-risk men, analyzing freedom from biochemical recurrence (BFS), metastasis free survival (MFS), cancer-specific survival (CSS), and overall survival (OS). Appropriate comparative tests were used. Survival estimates were derived from Kaplan-Meier life tables. Minimum follow-up for all patients included annual symptom assessments and prostate specific antigen (PSA) measurements. Biochemical recurrence was defined as a post-operative increase in PSA (≥0.2 ng/ml), metastasis was defined as radiographic evidence of extra-pelvic disease spread, and cancer-specific mortality was defined as death due to PCa. In order to reflect contemporary practice patterns, sub-analyses were also performed including only men with extended sampling (≥10 cores at biopsy)([@R9]) and who were treated in the modern Gleason grading era (adopted at our center in 2004) ([@R10]).

The final VHR criteria performance characteristics were also compared with all possible binary cut-points of the Cancer of the Prostate Risk Assessment scoring system (CAPRA), a validated pre-operative oncologic risk classification that yields a distinct integer score between 0 and 10. ([@R11]--[@R13]). Because calculation of CAPRA depends on proportion of positive biopsy cores, only patients with known total number of biopsy cores were included in this analysis (n=566). The median number of biopsy cores was 12.0, and 62% had extended sampling with ≥10 cores.

The two-tailed level of statistical significance was pre-defined as p \<0.05. Statistical analyses were performed with STATA 11.0 (StataCorp, College Station, Texas, USA).

Results {#S7}
=======

We first validated known risk factors for metastasis and cancer-specific mortality including number of NCCN high-risk features, biopsy Gleason sum, and volume of high-grade cancer (as assessed by proportion of positive cores on biopsy with Gleason pattern 4 or 5), all of which were significant predictors of metastasis and death in this cohort. In contrast, PSA, PSA velocity, and clinical stage were not prognostic for either outcome (data not shown). Alternate permutations of adverse risk factors (number of high-risk features, volume of high-grade cancer on biopsy, and pattern of high-grade cancer) comprised 28 alternate VHR criteria. Within these VHR test definitions, hazard ratios for metastasis ranged from 1.82--3.98 and those for cancer=specific mortality ranged from 1.86--4.82 ([Table 1](#T1){ref-type="table"}). VHR test definitions with hazard ratios in the highest quartile for *both* MFS *and* CSS were subject to multivariable analysis

Among the five VHR test definitions analyzed by multivariable modeling, 'primary pattern 5' had the highest adjusted hazard ratios but it included only 6.9% of the high-risk cohort; therefore it was not considered any further. Of the four remaining VHR test definitions, adjusted hazard ratios for metastasis and cancer-specific mortatlity were similar ([Table 2](#T2){ref-type="table"}), indicating nearly equivalent abilities to discriminate outcomes within the high-risk cohort. Subsequently the ultimate VHR definition was selected according to inclusion of the highest proportion of the high-risk cohort (15.1%) to maximize clinical utility. This definition included men presenting with: primary Gleason pattern 5, or ≥5 cores with Gleason sum 8--10, or multiple NCCN high-risk features (i.e. Gleason sum 8--10 and PSA \>20).

When compared to the remainder of the high-risk cohort, VHR men presented more commonly with clinical T3 disease (14.9% vs 5.8%, p\<0.001) and perineural invasion on biopsy (36.8% vs 24.4%, p=0.005) but had equivalent positive surgical margin rates (26.3% vs 28.5%, p=0.609) ([Table 3](#T3){ref-type="table"}). Median follow-up was 5.0 years in both the high-risk and VHR cohorts. VHR criteria discriminated men with significantly divergent BFS, MFS, CSS, and OS Kaplan-Meier curves (log-rank p\<0.001 for all measures) (Figure 2). At 10 years, BFS for VHR was 0.21 (95% C.I. 0.09, 0.36) compared to 0.41 (95% C.I. 0.36, 0.46) for the remainder of the high-risk cohort ([Table 4](#T4){ref-type="table"}). Ten-year MFS for VHR men was 0.37 (95% C.I. 0.20, 0.54) compared to 0.78 (95% C.I. 0.72, 0.83) for the remainder of the high-risk cohort ([Table 4](#T4){ref-type="table"}). Similarly, 10-year CSS for VHR men was 0.62 (95% C.I. 0.45, 0.76) compared to 0.90 (95% C.I. 0.85, 0.93) for high-risk men ([Table 4](#T4){ref-type="table"}). The independent contributions of each component of the VHR criteria were assessed in multivariable models ([Table S3](#SD3){ref-type="supplementary-material"}). All three components were significantly associated with risk of metastasis. In a sub-analysis of men diagnosed with extended biopsy sampling in the modern Gleason grading era (n=275), VHR criteria remained the strongest predictors of metastasis in univariate and multivariable analyses ([Table S4](#SD4){ref-type="supplementary-material"}).

Rates of additional treatment post-RP (adjuvant or salvage radiation, androgen deprivation and/or chemotherapy) were compared between the VHR and high risk groups. Post-operative, pre-metastatic treatments occurred in 51.8% of VHR men but only 35.2% of the remainder of the high-risk cohort (p=0.001) ([Table 3](#T3){ref-type="table"}).

Further, we evaluated our high risk cohort in regards to their CAPRA score. Like our dichotomous classifier, CAPRA has the advantage over typical nomograms of being fairly easy to apply in the clinical setting with minimal calculation. ([@R11]--[@R13])

Within the entire NCCN high risk cohort, the mean CAPRA score was 5.3 (median 5.0, range 2--9). No metastases or PCa-specific deaths were seen among men with CAPRA \<3 or ≥9, both of which contained small numbers of patients ([Table S1](#SD1){ref-type="supplementary-material"}). In unadjusted ([Table S2](#SD2){ref-type="supplementary-material"}) and adjusted ([Table 5](#T5){ref-type="table"}) models, the final VHR criteria, compared with all CAPRA cut-points, was the only significant predictor of both MFS and CSS, though multiple CAPRA cut-points were significantly associated with MFS. The CAPRA cut-point that best discriminated MFS and CSS was 6. In MFS and CSS survival curves stratified by CAPRA ≥6 and the VHR criteria, MFS stratified similarly between the two different criteria, but the log-rank p-value for CSS by CAPRA ≥6 was not significant (p=0.140). Among 28 men with intermediate-risk CAPRA (3 to 5) who subsequently developed metastases, 4/28 (14.3%) met VHR criteria.

Discussion {#S8}
==========

After systematic evaluation of adverse prognostic variables, we report criteria that dichotomize men with NCCN high-risk PCa groups with distinct clinical outcomes. The very-high-risk (VHR) group is defined by the following criteria at diagnosis: primary Gleason pattern 5, or ≥5 cores with Gleason sum 8--10, or multiple NCCN high-risk features. VHR PCa defined in this way has an estimated prevalence of 15.1% of high-risk PCa. Furthermore, VHR criteria identify a subgroup of men within high-risk disease who have significant oncologic disparities: a 41% worse MFS and a 27% worse CSS at 10 years.

By design, we studied only pre-treatment variables, because pathologic data (as reported in [Table 3](#T3){ref-type="table"}), are not pertinent to pre-treatment risk stratification or consideration of initial management options. D'Amico et al have previously shown that PSA velocity \>2.0ng/ml/yr is an independent predictor of worse CSS after RP. ([@R14]) In our cohort higher PSA velocities were not associated with MFS or CSS, which may be related to the relatively small sample size of men with adequate preoperative PSA data to allow velocity calculations (n=234). When ranking hazard ratios, we focused on metastasis and cancer-specific mortality as endpoints most relevant to the biological behavior of PCa. Biochemical recurrence after RP in high-risk men is extremely common (over 60% at 10 years) ([@R6]) but does not have a direct impact on symptoms or further therapy. ([@R8]) Similarly, all-cause mortality is an endpoint confounded by co-morbidities: competing-risks mortality can exceed 40% at 10 years. ([@R15]) Thus we felt the most appropriate study design to define VHR criteria should evaluate the association of commonly available pre-treatment variables with MFS and CSS. ([@R16])

When evaluating MFS and CSS between the VHR cohort and remaining high-risk men, it is important to consider 1) follow-up and 2) additional therapies that were administered after RP. Median follow-up was 5.0 years in both groups, thus strengthening the comparison of incident cancer-related events. As shown in [table 3](#T3){ref-type="table"}, rates of additional therapies (radiation, androgen deprivation, and/or chemotherapies) after RP (and prior to metastasis) were higher among VHR men (52% versus 35%). The reasons for this difference are unknown as triggers for secondary therapies were not available for analysis. Historically, we have we have favored salvage treatments reserved for evidence of clinical metastasis and/or rapid PSA doubling time. These therapies may have been too delayed to alter VHR patients' clinical course, which suggests that the higher rate of pre-metastatic secondary treatments in VHR men reflected their more aggressive cancer rather than treating cancer progression, that VHR men may be better candidates therefore for aggressive adjuvant rather than salvage therapies, or that our best available systemic therapies are inadequate to treat VHR PCa, thus providing a greater sense of urgency for clinical trials to investigate neoadjuvant and adjuvant agents that can be truly therapeutic for aggressive PCa.

Other investigators have developed tools to predict MFS and CSS after PCa treatment. Several nomograms rely on post-operative data such as pathologic stage and PSA kinetics to predict metastasis ([@R17]--[@R20]) or cancer-specific death. ([@R21]--[@R24])

Tools to predict MFS and CSS using only pre-treatment variables are less common. For example some investigators have examined prostate cancer-specific mortality after curative local therapy in men stratified by the original D'Amico classification, ([@R25],[@R26]) though as previously discussed, the D'Amico and NCCN high-risk strata encompass a broad range of outcomes. One nomogram (Kattan et al) uses pre-treatment PSA, clinical stage, and biopsy Gleason sum to predict the 5-year probability of metastasis after external beam radiotherapy. ([@R27]) Nomograms, which are typically complex multivariable tools, provide accurate risk estimates for groups of patients, but they require paper- or software-based calculation, which is potentially cumbersome to apply in the live clinical setting. ([@R16])

A system that improves on the difficulty-of-use of multivariable nomograms is CAPRA, originally developed to predict biochemical recurrence after RP using pre-operative patient and tumor characteristics. ([@R11]--[@R13]) CAPRA requires minimal calculation, and it correlates with the development of metastasis after RP. ([@R28],[@R29]) Interestingly, in our cohort of NCCN high risk men, 59.2% were classified as CAPRA low (1.6) or intermediate (57.6) risk. When the high risk group was stratified by CAPRA, men meeting NCCN high risk criteria that additionally CAPRA 6 had MFS similar to VHR men.

In a study by Cooperberg et al ([@R28]) (similar findings were found by Budäus et al ([@R29])), among high-risk men (defined as CAPRA ≥6), the range of the worst and best 10-year MFS was 79.2% to 84.7% (5.5 point difference), compared to 36.9% to 77.9% (41.0 point difference) within high-risk men stratified by VHR criteria. Among the NCCN high-risk cohort in the present study, though CAPRA ≥5 to ≥7 was significantly associated with MFS, no CAPRA score dichotomized the high-risk cohort in a way that was associated with CSS. These findings suggest that VHR criteria may better differentiate high-risk men who perform well compared to the group that suffers with disproportionately worse MFS and CSS. However, nearly one third of high-risk men who developed metastases did not meet either CAPRA ≥6 or VHR, suggesting a need for future classifiers (such as genomic predictors) to achieve superior risk-stratification. ([@R30])

The objective of the VHR classification is to identify those who suffer the worst oncologic outcomes despite curative local treatments, thus informing additional treatment decisions. Among established therapies, VHR men may be suitable candidates for early radiation therapy and/or and androgen deprivation after RP, which is a clinical dilemma that has been raised by other investigators. ([@R31],[@R32]) VHR criteria may also aid in patient selection for clinical trials. Selecting men with localized PCa who are most prone to develop subsequent adverse oncologic outcomes may help clinical investigations illustrate which novel therapeutics can meaningfully alter the course of aggressive PCa.

There are several limitations. First, it was retrospective and therefore vulnerable to unrecognized selection bias\--there were no explicit criteria to select high-risk men for surgery. Second, this is a single-center study where the cohort is largely referral-based and the treating surgeons are high-volume. The outcomes reported may therefore not reflect community-based or international practice patterns, and external validation of the VHR criteria are required before routine use. Third, although all tissues were analyzed centrally, pathological specimens were not re-reviewed. Thus in order to correct for changes in Gleason grading over time, we performed additional analyses including men diagnosed in the modern grading era, which commenced at our center in 2004. Additionally, all patients in this study underwent RP, and though there has been increasing evidence to support the use of surgery in high-risk men ([@R33],[@R34]), any pre-treatment risk stratification, including VHR, is relevant to men considering all management approaches.

Conclusions {#S9}
===========

Criteria for very-high-risk localized PCa as defined in this population are any primary Gleason pattern 5, or ≥5 cores with Gleason sum 8--10 at biopsy, or multiple NCCN high-risk features present at diagnosis. These criteria identify a group of men within the current NCCN high-risk category who are at greatest risk of developing metastasis or cancer-related death despite conventional treatment. Use of the VHR classification scheme can help improve pre-treatment risk stratification and help to select those patients who have the most to gain from multimodal treatments or novel clinical trial approaches.
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###### 

Univariate hazard ratios for metastasis, cancer-specific mortality, and all-cause mortality among 28 tested very-high-risk definitions

                                                                                                Metastasis   Cancer-specific mortality   All-cause mortality                                                                       
  -------- ------------------------------------------------------------------------------------ ------------ --------------------------- --------------------- ---------- --------- ------------ ---------- --------- ------------ -------------
  1        Any pattern 5 or pattern 4 + PSA \>20 or pattern 4 + ≥cT3a                           2.26         \<0.001                     1.53, 3.32            2.54       \<0.001   1.52, 4.26   1.80       0.002     1.24, 2.61   328 (43.6%)
  2        Any pattern 5 or Gleason 8 + PSA \>20 or Gleason 8 + ≥cT3a                           2.38         \<0.001                     1.60, 3.55            3.78       \<0.001   2.31, 6.18   2.55       \<0.001   1.74, 3.74   190 (25.2%)
  3        Multiple high-risk features                                                          2.53         \<0.001                     1.44, 4.43            2.91       \<0.001   1.55, 5.45   2.12       0.005     1.25, 3.59   45 (6.0%)
  4        Any pattern 5                                                                        2.16         \<0.001                     1.42, 3.27            3.44       \<0.001   2.08, 5.69   2.47       \<0.001   1.66, 3.68   171 (22.7%)
  **5**    **Primary pattern 5**                                                                **3.98**     \<0.001                     2.28, 6.96            **4.82**   \<0.001   2.43, 9.58   **3.20**   \<0.001   1.78, 5.76   52 (6.9%)
  6        Any pattern 5 or multiple high-risk features                                         2.40         \<0.001                     1.62, 3.55            3.90       \<0.001   2.39, 6.36   2.57       \<0.001   1.76, 3.75   197 (26.2%)
  7        Any pattern 5 or ≥4 cores with pattern 4                                             2.31         \<0.001                     1.57, 3.39            2.97       \<0.001   1.81, 4.89   2.05       \<0.001   1.39, 3.01   286 (38.0%)
  8        Any pattern 5 or ≥4 cores with pattern 4 or multiple high-risk feat                  2.54         \<0.001                     1.73, 3.73            3.28       \<0.001   2.00, 5.39   2.06       \<0.001   1.42, 3.00   304 (40.4%)
  **9**    **Primary pattern 5 or multiple high-risk features**                                 **3.15**     \<0.001                     2.02, 4.91            **3.73**   \<0.001   2.20, 6.33   **2.57**   \<0.001   1.67, 3.97   90 (12.0%)
  10       Primary pattern 5 or ≥4 cores with pattern 4                                         2.55         \<0.001                     1.70, 3.83            2.52       \<0.001   1.44, 4.43   1.62       0.038     1.03, 2.66   201 (26.7%)
  11       Primary pattern 5 or ≥4 cores with pattern 4 or multiple high-risk feat              2.78         \<0.001                     1.89, 4.10            2.76       \<0.001   1.66, 4.57   1.76       0.007     1.17, 2.66   227 (30.1%)
  12       Any pattern 5 or max pattern 4 or 5 per core \>50%                                   2.31         \<0.001                     1.56, 3.41            2.32       \<0.001   1.41, 3.81   1.82       0.002     0.25, 2.65   368 (48.9%)
  13       Any pattern 5 or max pattern 4 or 5 per core \>50% or mult hi risk feat              2.63         \<0.001                     1.76, 3.92            2.74       \<0.001   1.65, 4.55   1.92       0.002     1.32, 2.80   384 (51.0%)
  14       Primary pattern 5 or ≥4 cores with pattern 4/5                                       2.51         \<0.001                     1.67, 3.77            2.50       \<0.001   1.42, 4.40   1.63       0.042     1.02, 2.63   204 (27.1%)
  15       Primary pattern 5 or ≥4 cores with pattern 4/5 or mult high-risk feat                2.74         \<0.001                     1.86, 4.05            2.74       \<0.001   1.65, 4.54   1.75       0.007     1.16, 2.64   230 (30.5%)
  16       Primary pattern 5 or ≥4 cores with pattern 4/5 or PNI                                2.12         \<0.001                     1.45, 3.10            1.86       \<0.001   1.14, 3.05   1.32       0.150     0.90, 1.94   308 (40.9%)
  17       Primary pattern 5 or PNI                                                             2.21         \<0.001                     1.51, 3.23            1.95       \<0.001   1.18, 3.20   1.42       0.076     0.96, 2.10   234 (31.1%)
  18       Primary pattern 5 or ≥1 core with sum 8--10 or multiple high-risk features           1.82         \<0.001                     1.22, 2.70            2.93       \<0.001   1.71, 5.05   1.84       0.002     1.25, 2.69   455 (60.4%)
  19       Primary pattern 5 or ≥2 cores with sum 8--10 or multiple high-risk features          2.25         \<0.001                     1.54, 3.30            2.79       \<0.001   1.71, 4.56   1.75       0.004     1.19, 2.56   267 (35.5%)
  20       Primary pattern 5 or ≥3 cores with sum 8--10 or multiple high-risk features          2.72         \<0.001                     1.83, 4.04            3.17       \<0.001   1.92, 5.23   2.04       0.001     1.36, 3.07   176 (23.4%)
  21       Primary pattern 5 or ≥4 cores with sum 8--10 or multiple high-risk features          2.55         \<0.001                     1.68, 3.87            3.06       \<0.001   1.82, 5.13   2.05       0.001     1.34, 3.13   138 (18.3%)
  **22**   **Primary pattern 5 or ≥5 cores with sum 8--10 or multiple high-risk features**      **3.21**     \<0.001                     2.10, 4.89            **3.54**   \<0.001   2.10, 5.96   **2.39**   \<0.001   1.56, 3.67   114 (15.1%)
  **23**   **Primary pattern 5 or ≥6 cores with sum 8**-**10 or multiple high-risk features**   **3.22**     \<0.001                     2.10, 4.96            **3.74**   \<0.001   2.22, 6.30   **2.52**   \<0.001   1.64, 3.87   102 (13.5%)
  **24**   **Primary pattern 5 or ≥7 cores with sum 8**-**10 or multiple high-risk features**   **3.35**     \<0.001                     2.17, 5.17            **3.90**   \<0.001   2.31, 6.57   **2.63**   \<0.001   1.71, 4.03   94 (12.5%)
  25       Primary pattern 5 or mult hi risk features or PNI                                    2.41         \<0.001                     1.65, 3.52            2.44       \<0.001   1.50, 3.97   1.70       0.005     1.17, 2.46   257 (34.1%)
  26       Primary pattern 5 or mult hi risk features or PNI+ ≥1 cores with Gleason sum 8--10   2.83         \<0.001                     1.90, 4.20            3.17       \<0.001   1.92, 5.23   2.22       \<0.001   1.49, 3.30   191 (25.4%)
  27       Primary pattern 5 or mult hi risk features or PNI+ ≥2 cores with Gleason sum 8--10   3.04         \<0.001                     2.04, 4.53            3.20       \<0.001   1.92, 5.31   2.15       \<0.001   1.43, 3.25   152 (20.2%)
  28       Primary pattern 5 or mult hi risk features or PNI+ ≥3 cores with Gleason sum 8--10   3.20         \<0.001                     2.12, 4.82            3.26       \<0.001   1.94, 5.46   2.18       \<0.001   1.43, 3.33   125 (16.6%)

###### 

Hazard ratios for metastasis, cancer-specific mortality, and all-cause mortality among top-ranking definitions, adjusted for age, year of surgery, and perineural invasion

                                                                                             Metastasis   Cancer-specific mortality   All-cause mortality                                                                       
  -------- --------------------------------------------------------------------------------- ------------ --------------------------- --------------------- ---------- --------- ------------ ---------- --------- ------------ -------------
  5        Primary pattern 5                                                                 4.11         \<0.001                     2.35, 7.17            4.70       \<0.001   2.37, 9.33   3.14       \<0.001   1.75, 5.63   52 (6.9%)
  9        Primary pattern 5 or multiple high-risk features                                  2.86         \<0.001                     1.81, 4.50            3.33       \<0.001   1.93, 5.76   2.56       \<0.001   1.65, 4.00   90 (12.0%)
  **22**   **Primary pattern 5 or ≥5 cores with sum 8--10 or multiple high-risk features**   **2.93**     \<0.001                     1.90, 4.53            **3.22**   \<0.001   1.88, 5.53   **2.44**   \<0.001   1.57, 3.79   114 (15.1%)
  23       Primary pattern 5 or ≥6 cores with sum 8--10 or multiple high-risk features       2.92         \<0.001                     1.88, 4.54            3.37       \<0.001   1.96, 5.77   2.53       \<0.001   1.63, 3.92   102 (13.5%)
  24       Primary pattern 5 or ≥7 cores with sum 8--10 or multiple high-risk features       3.05         \<0.001                     1.96, 4.75            3.50       \<0.001   2.04, 6.00   2.62       \<0.001   1.96, 4.07   94 (12.5%)

###### 

Pre-operative & pathologic characteristics of very-high-risk men

                                                                                  JHU high-risk       JHU very-high-risk   p
  ------------------------------------------------------------------------------- ------------------- -------------------- ---------------------------------------------
  N                                                                               639                 114                  
                                                                                                                           
  Median Age (IQR)                                                                60.0 (54.0, 64.0)   59.0 (54.0, 63.0)    0.482[\*](#TFN1){ref-type="table-fn"}
                                                                                                                           
  AA race                                                                         74 (11.6%)          10 (8.8%)            0.380
                                                                                                                           
  Positive family history                                                         128/356 (36.0%)     23/64 ((35.9%)       0.998
                                                                                                                           
  Median PSA (ng/dl) (IQR)                                                        11.1 (5.5, 24.1)    10.2 (6.2, 21.4)     0.597[\*](#TFN1){ref-type="table-fn"}
                                                                                                                           
  Median PSA density (IQR)                                                        0.43                0.35                 0.806[\*](#TFN1){ref-type="table-fn"}
                                                                                                                           
  PSA \>20 ng/dl                                                                  261 (40.8%)         36 (31.6%)           0.062
                                                                                                                           
  Clinical stage                                                                                                           **\<0.001**
  T1                                                                              351 (54.9%)         45 (39.5%)           
  T2                                                                              251 (39.3%)         52 (45.6%)           
  T3                                                                              37 (5.8%)           17 (14.9%)           
                                                                                                                           
  Biopsy Gleason                                                                                                           **\<0.001**[\^](#TFN2){ref-type="table-fn"}
  ≤6                                                                              164 (25.7%)         3 (2.6%)             
  7                                                                               134 (30.0%)         4 (3.5%)             
  8                                                                               278 (43.5%)         50 (43.9%)           
  9                                                                               63 (9.9%)           52 (45.6%)           
  10                                                                              0 (0%)              5 (4.4%)             
                                                                                                                           
  Primary pattern 5                                                               0 (0%)              52 (45.6%)           **\<0.001**[\^](#TFN2){ref-type="table-fn"}
                                                                                                                           
  Multiple high-risk features                                                     0 (0%)              45 (39.5%)           **\<0.001**[\^](#TFN2){ref-type="table-fn"}
                                                                                                                           
  ≥5 cores with Gleason sum 8                                                     0 (0%)              36 (31.6%)           **\<0.001**[\^](#TFN2){ref-type="table-fn"}
                                                                                                                           
  Perineural invasion present on biopsy                                           156 (24.4%)         42 (36.8%)           **0.005**
                                                                                                                           
  Laparoscopic or Robotic RP                                                      59 (9.2%)           12 (10.5%)           0.663
                                                                                                                           
  Pathologic stage                                                                                                         **\<0.001**
  pT2N0                                                                           206 (32.2%)         21 (18.4%)           
  pT3aN0                                                                          287 (44.9%)         43 (37.7%)           
  pT3bN0                                                                          78 (12.2%)          22 (19.3%)           
  pN1                                                                             68 (10.6%)          28 (24.6%)           
                                                                                                                           
  Pathologic Gleason                                                                                                       **\<0.001**[\^](#TFN2){ref-type="table-fn"}
  ≤6                                                                              93 (14.6%)          1 (0.9%)             
  7                                                                               294 (46.0%)         27 (23.7%)           
  8                                                                               126 (19.7%)         36 (31.6%)           
  9                                                                               124 (19.4%)         47 (41.2%)           
  10                                                                              0 (0%)              3 (2.6%)             
                                                                                                                           
  Positive surgical margin                                                        182 (28.5%)         30 (26.3%)           0.609
                                                                                                                           
  Received radiation, androgen deprivation, or chemotherapy prior to metastasis   225 (35.2%)         59 (51.8%)           **0.001**
                                                                                                                           
  Median follow-up (years) (IQR)                                                  5.0 (2.0, 10.0)     5.0 (3.0, 8.0)       0.430[\*](#TFN1){ref-type="table-fn"}

p-value derived from Wilcoxon-Mann-Whitney test, IQR=interquartile range

p-value derived from Fisher's exact test

###### 

Five- & 10-year survival probabilities[\*](#TFN3){ref-type="table-fn"} (BFS, MFS, CSS, & OS) stratified by very-high-risk classification

                        JHU high-risk   JHU very-high-risk                                   
  --------- ----------- --------------- -------------------- ----------- ----------- ------- -------
  **BFS**   5           **0.503**       0.457                0.548       **0.275**   0.182   0.376
  10        **0.412**   0.360           0.462                **0.206**   0.090       0.356   
  **MFS**   5           **0.914**       0.884                0.937       **0.749**   0.630   0.835
  10        **0.779**   0.722           0.826                **0.369**   0.198       0.542   
  **CSS**   5           **0.976**       0.956                0.987       **0.922**   0.833   0.965
  10        **0.895**   0.850           0.928                **0.622**   0.447       0.755   
  **OS**    5           **0.951**       0.927                0.968       **0.858**   0.757   0.920
  10        **0.833**   0.782           0.872                **0.579**   0.416       0.711   

Kaplan-Meier life table estimates

###### 

Hazard ratios for metastasis and cancer-death comparing all possible CAPRA cut-points and JHH Very High Risk criteria, among 566 NCCN high-risk men with evaluable CAPRA scores, adjusted for age, year of surgery, and perineural invasion

                                                                                Metastasis   Cancer-specific mortality                                                                                      
  ----------------------------------------------------------------------------- ------------ --------------------------- ---------------- ------------ ---------- ----------- ---------------- ------------ -------------
  CAPRA ≥4                                                                      2.81         0.305                       0.39, 20.3       0.6100       1.12       0.913       0.15, 8.23       0.6599       540 (95.4%)
  CAPRA ≥5                                                                      **3.08**     **0.009**                   **1.32, 7.18**   **0.6531**   1.01       0.980       0.41, 2.49       0.6592       405 (71.6%)
  CAPRA ≥6                                                                      **2.48**     **0.001**                   **1.47, 4.20**   **0.6487**   1.40       0.351       0.69, 2.82       0.6553       231 (40.8%)
  CAPRA ≥7                                                                      **2.27**     **0.003**                   **1.33, 3.87**   **0.6538**   1.77       0.135       0.84, 3.73       0.6676       99 (17.5%)
  CAPRA ≥8                                                                      1.65         0.220                       0.74, 3.67       0.6161       2.00       0.134       0.81, 4.94       0.6560       34 (6.0%)
  Primary pattern 5 or ≥5 cores with sum 8--10 or multiple high-risk features   **2.26**     **0.005**                   **1.28, 4.00**   **0.6413**   **2.35**   **0.031**   **1.08, 5.12**   **0.6874**   93 (16.4%)

[^1]: Equal contribution senior authors
